Markets
Bill Hwang.
Archegos founder Bill Hwang (Michael Santiago / Getty Images)
Weird Money

The jury that convicted Bill Hwang of fraud had to get a "crash course in finance" first

Bill Hwang was found guilty on 10 of 11 charges regarding his 2021 hedge fund meltdown.

Jack Raines

The collapse of Bill Hwang’s Archegos Capital is my favorite finance story of the 2020s. A very brief overview: Hwang, a Tiger Global alumnus who once claimed that God loved Google because it provided “the best information to everybody,” lost $20 billion in two days in March 2021 (and $36 billion from his portfolio’s peak), after his leveraged bets on ViacomCBS, Discovery, Baidu, Vipshop, Farfetch, and various other Chinese tech tanked. The meltdown wiped out $100 billion in equity value of his portfolio companies, cost global banks that had made loans to Archegos $10 billion, and eventually led to Credit Suisse collapsing.

Hwang was subsequently arrested in 2022 and charged with 11 counts of racketeering, securities fraud, wire fraud, and market manipulation, and yesterday, he was convicted on 10 of 11 charges. From Bloomberg:

Both men were convicted of defrauding Archegos counterparties like Credit Suisse Group AG and UBS Group AG by lying to them about the firm’s trading activity and the level of risk in its portfolio. Hwang was separately found guilty of manipulating several stocks, including the former ViacomCBS, though he was acquitted with regard to one stock. Both men were also convicted of participating in racketeering conspiracy.

One of my favorite concerns that arose during Hwang’s trial was whether or not the jury would be able to grasp what exactly Hwang did, and what exactly he was being charged with, in order to deliver a verdict. From Bloomberg:

The panel of New Yorkers, who the judge has wryly said would be getting a crash course in “Finance 101,” will weigh a raft of complicated exhibits and reams of testimony. The jurors must decide whether Hwang illegally pumped up the price of stocks he was investing in and duped such sophisticated players as UBS Group AG, Morgan Stanley and Goldman Sachs Group Inc. about the sky-high risk to which he was exposing them.

“This is more complex than many other cases, and that’s an issue,” UCLA law professor James Park said in an interview. “It will be challenging for the jury to distinguish between trading meant to artificially manipulate the price and trading of a stock you think is valuable.”

The jurors, most of whom don’t have any financial background, will now determine Hwang’s fate.

The jury, a few members of which I’ve listed below, is not exactly comprised of financial market experts:

  • A research scientist at the American Museum of Natural History who enjoys snowboarding, mountain biking, hiking, and backpacking.

  • A Parsons School of Design graduate now working as a freelance graphic designer for companies.

  • A retired Con Edison worker born in Aruba who served in the military and lives in the Bronx. “I have a lot of spare time,” he told the judge, prompting laughter from the packed courtroom.

  • A Manhattan native who teaches first grade on the Upper West Side. She loves fiction and regularly reads the New York Times as well as the New Yorker.

  • A retired train inspector for the New York City Transit Authority who likes woodworking and home-improvement projects.

One thing I admire about the American legal system is that, while it takes years of laborious study and practice to become an attorney, and even more so to become a judge, a first-grade teacher and a freelance graphic designer can determine the outcome of the biggest securities fraud case of the century. So, what exactly did Hwang do?

Normally, hedge funds such as Archegos must disclose their stakes in various companies through 13-F filings, but this rule didn’t apply to Archegos, because Hwang’s fund didn’t “directly” own the stocks it was invested in. Instead, Archegos used “Total Return Swaps” to borrow money and take outsized positions in each company.

In a Total Return Swap, a hedge fund pays an investment bank, such as Goldman Sachs, a fee in exchange for that bank buying assets, such as stocks. The bank then pays out the stocks’ returns to the hedge fund, but if the stocks’ prices decline, the hedge fund owes the bank money. If the hedge fund used leverage (borrowed money from the bank), it may have to post more collateral as the price declines, or the bank would sell some of its stocks, likely sending stock prices lower.

Archegos held Total Return Swaps with several banks, the firm was borrowing up to 5x its invested capital by March 2021 (giving it exposure to $160 billion in equities on $36 billion in its own assets), it was piling into the same basket of stocks through its swaps with multiple banks, and none of the banks knew that Archegos was investing in the same stocks across its other return swaps because Archegos didn’t have to disclose the stocks associated with its return swaps.

To be clear, highly leveraged trades using Total Return Swaps, while, obviously reckless, are, on their own, legal. If making stupid trades using leverage was felony, half of the accounts on Wall Street Bets would be in prison. What is not legal, however, is lying to your counterparties about your portfolio so they’ll wire you $173 million to meet other margin calls. From Bloomberg:

Former UBS risk manager Bryan Fairbanks was the first witness to take the stand in the trial, and he vividly described being on the other end of Archegos’ lies.

Fairbanks described being told that Archegos’ portfolio largely comprised highly liquid megacap tech stocks like Apple Inc. and Amazon.com Inc., and that its trading in companies like Viacom and Chinese online education company GSX Techedu Inc. was unique to UBS.

I am not a risk manager at a large bank. However, if I were a risk manager at a large bank, and I had a client facing a margin call, and that client told me told me that their entire portfolio, including leveraged positions with other banks, was invested in the same Chinese tech stocks and archaic media companies that caused the margin call with my bank, I would probably be less inclined to wire them $173 million the day before their margin call than if they lied and said the rest of the portfolio was in Apple and Amazon.

It also isn’t great when part of your defense is that your trading was part of a “long-term strategy” and the stocks moved for “other reasons than the firm’s alleged manipulation,” and then your former trader takes the stand and says the complete opposite:

The former trader worked closely with Hwang and offered damaging testimony about how his boss micromanaged his team to goose stocks to certain prices and also directed Tomita to lie to Archegos’ counterparties about the firm’s portfolio.

Tomita testified that Hwang instructed his traders to do “the opposite” of what a “normal fund” would. He noted that normal funds would try to build up their positions at the lowest cost and try to minimize the impact of their own trading on prices. At Archegos, Tomita said, “I could see that it was me that generated the stock price.”

To be fair, the stock charts of Hwang’s otherwise unrelated investments do look a bit “goosed,” no?

Ultimately, while the jury may not understand the minute details of total return swaps, it didn’t take them long to decide that Hwang lied to his counterparties (bad!) and manipulated stock prices (also bad!).

More Markets

See all Markets
markets
Nate Becker

Health insurance stocks lose steam as Trump says he’ll lobby insurers for lower prices

Shares of health insurance companies dropped Friday afternoon, as President Trump said he would ask insurers to meet with him in the coming weeks to seek lower prices.

Stocks including Humana, UnitedHealthcare, Cigna, CVS Health, and Elevance Health all either pared gains or went further into the red after Trump’s remarks, which came at the end of a press event to announce pricing deals with nine drugmakers.

“I’m going to call a meeting of the big insurance companies that have gotten so rich,” Trump said, noting that he would lobby them for lower prices.

“I would say that maybe with one talk, they would be willing to cut their prices by 50, 60, or 70%. They’ve made a fortune.”

markets

Rivian’s surge continues as stock reaches highest level since December 2023 on analyst upgrades

Shares of EV maker Rivian are on pace to close up double digits for the second day in a row on Friday as bullish investors pour into the stock following analyst upgrades.

Rivian shares were up more than 10% on Friday afternoon, with the stock climbing to its highest level since December 2023.

Webush’s Dan Ives boosted his Rivian price target by 56% to $25 in a note on Friday morning. The analyst wrote that 2026 is a “prove-me” year for the automaker, with its lower-cost R2 model set to launch in the first half.

Ives’s note follows a separate optimistic bit of analysis from Baird, which also boosted its Rivian price target to $25 in a note on Thursday.

If today's gains hold, Friday will mark the third day of double-digit gains for Rivian in the past six trading days. An “AI Day” event that saw the automaker detail autonomous updates and tease a robotaxi plan started the recent run.

markets
Luke Kawa

The neoclouds are shooting back up into the stratosphere

Investors’ faith in tech CEOs’ pursuit of digital God has seemingly been restored for now, sparking an intense rally in the speculative AI players that had been in full-on meltdown mode over concerns that the boom had passed its best-before date.

The data center companies colloquially known as the “neoclouds” — CoreWeave, Nebius, IREN, and Cipher Mining — are up more than double digits over the past two sessions, as of 10:40 a.m. ET.

The past 48 hours have brought a steady drumbeat of positive news for the AI theme.

CoreWeave received a vote of confidence from Wall Street as Citi resumed coverage with a buy rating and price target of $135. Oracle, the epicenter of AI credit concerns, has seen a reversal in its fortunes as it nears an acquisition of TikTok’s US operations. And OpenAI’s fundraising efforts appear be going so well that its reported valuation has gone up in back-to-back days.

Before that, Micron’s earnings reaffirmed the intense demand for AI compute, which continues to outstrip supply — a positive sign for the neoclouds. The macro backdrop is also turning perhaps a bit more in favor of lower interest rates, as CPI inflation came in well below expectations.

Snoop Dogg Performs At OVO Hydro Glasgow

Marijuana rescheduling could mean more investment in US weed stocks. There aren’t many ways in.

“Yes, institutional capital will go into the underlying names. The question is: How fast?" one weed company chairman said.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.